1 – 10 of 69
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hematological and renal toxicity in mice after three cycles of high activity [177Lu]Lu-PSMA-617 with or without human α1-microglobulin
(
- Contribution to journal › Article
- 2022
-
Mark
Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
(
- Contribution to journal › Article
- 2021
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
-
Mark
Humanization, radiolabeling and biodistribution studies of an igg1-type antibody targeting uncomplexed psa for theranostic applications
(
- Contribution to journal › Article
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
(
- Contribution to journal › Article
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
(
- Contribution to journal › Article
- 2020
-
Mark
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
2020) In Proceedings of the National Academy of Sciences of the United States of America 117(26). p.15172-15181(
- Contribution to journal › Article
- 2019
-
Mark
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics
(
- Contribution to journal › Article
-
Mark
Harnessing androgen receptor pathway activation for targeted alpha particle radioimmunotherapy of breast cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer
(
- Contribution to journal › Article